Clinical Trials Browser

Phase 2/3 × Myasthenia Gravis × fludarabine × Clear all

NCT06193889 2026-01-30

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Phase 2/3 Recruiting

Autoimmune Diseases, Myasthenia Gravis